Hanmi's Q2 Operating Profit More Than Doubles on 29% Sales Jump

Hanmi Pharmaceutical’s second quarter was driven less by volume than by pricing power: revenue rose 29.3% year on year to 467.2 billion won, but operating profit climbed 116.9% to 131 billion won — meaning roughly four times as much incremental profit as the top line alone would imply. The provisional consolidated figures were filed on July 28, part of a dense day of quarterly disclosures to Korea’s Financial Supervisory Service that also included LG H&H, Krafton, Korea Aerospace Industries, Nexen Tire, HanAll Biopharma and NBT.

The Margin Story Behind the Headline Number

Working backward from the growth rates, Hanmi Pharm earned about 60 billion won in operating profit on roughly 361 billion won of revenue in the same quarter last year — an operating margin near 17%. This quarter that margin sits at 28%. A gain of eleven percentage points in twelve months is not something a distribution business produces by selling more of the same mix; it points to a shift toward products carrying materially higher gross margins, or to revenue that arrives with little associated cost of goods, such as licensing and milestone income.

Net profit rose 95.5% to 84 billion won. The gap between operating profit growth (116.9%) and net profit growth (95.5%) means the below-the-line items — financing costs, taxes, non-operating charges — grew faster than the core business, or that a prior-year non-operating gain is not repeating. On a first-half basis, cumulative revenue reached 860.2 billion won, which implies the June quarter carried more than half the half-year total.

The Holding Company Moves Too, But Differently

Hanmi Science, the group’s holding entity, reported consolidated second-quarter revenue of 367.9 billion won, up 8.7%, with operating profit of 59.2 billion won (+70.9%) and net profit of 43.7 billion won (+54.2%). Its operating margin worked out to about 16%, up from roughly 10% a year earlier.

The two disclosures move in the same direction but at very different speeds, and the holding company’s consolidated revenue comes in below that of the operating pharmaceutical unit — a relationship that does not follow the usual arithmetic of a parent consolidating its subsidiary. Both filings are provisional and unaudited, and the reconciliation is the thing to check against the audited statements rather than to explain away now. What is unambiguous in both sets of numbers is the direction of profitability: earnings at the operating level are expanding far faster than sales at both entities.

Why This Reads as a Business-Model Shift

Korean pharmaceutical companies have spent the past decade trying to convert domestic generic and over-the-counter cash flow into something with export economics — original compounds, out-licensed pipelines, and contract income from overseas partners. Those revenue lines behave differently from prescription sales: they are lumpy, they arrive quarter to quarter without warning, and they carry almost no incremental cost. A quarter in which operating profit grows four times faster than revenue has that fingerprint.

The corollary is that such quarters are hard to annualize. If the margin expansion came from recurring product mix, the 28% level should persist into the second half. If it came from event-driven income, the comparison base for next year’s second quarter becomes punishing. Hanmi has not, in these provisional filings, broken out which it is.

What the Numbers Do Not Yet Say

The provisional disclosure format carries top-line, operating and net figures without segment detail, so the composition of the quarter — domestic versus export, product versus licensing — stays closed until the full financial statements and the quarterly report land. Two things will settle the interpretation: a segment breakdown showing whether overseas or contract revenue drove the gap, and the third-quarter print, which will show whether 28% was a level or a spike.